Sign up USA
Proactive Investors - Run By Investors For Investors

Aptose Biosciences reaches China distribution deal for CG-806 with South Korea's CrystalGenomics

The pact brings the drug therapy for leukemia to China, Hong Kong and Macau markets
China map
CG-806 is a small molecule that is being developed for the treatment of acute myeloid leukemia

Aptose Biosciences (NASDAQ:APTO) today unveiled a ground-breaking licensing agreement with South Korea’s CrystalGenomics Inc to sell its drug therapy CG-806 in China, Hong Kong and Macau.

CG-806 is a small molecule that is being developed for the treatment of acute myeloid leukemia, B-cell malignancies and additional blood cancers.

Aptose shares climbed 11.8% to US$4.22 in pre-market trade on the back of the company’s deal.

Under the terms, Aptose, which is based in San Diego, California, will pay CrystalGenomics US$3m up front as well as make additional payments for commercial-based milestones and royalties. The deal's value for the China territory, including the upfront payment, could reach as much as US$125mln.

Dr. William Rice, Aptose’s president and chief executive, said pre-clinical work with CG-806 has shown its superior ability to kill B-cell malignancy relative to other treatments.

“We believe that CG-806 has the potential to serve as a transformational agent for multiple hematologic cancers,” he said.

Aptose has been conducting investigational new drug-enabling studies with CG-806 as well as numerous preclinical studies.

View full APS profile View Profile

Aptose Biosciences Timeline

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use